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Summarv Serum bone alkaline phosphatase (BALP). serum carboxv-terminal propeptide of type I procollagen
(PICP) and serum bone gla protein (BGP) as markers of bone formation. serum carboxv-terminal telopeptide
of type I collagen (ICTP) as a marker of collagen resorption and fasting molar ratio of urinarv calcium to
creatimne (CaCr) and serum parathvToid hormone (PTH) were determined in two groups of cancer patients: 48
with adsvanced or metastatic disease with negatise bone scan and 174 with bone metastases categorised as
haVing lvtic. mixed or blastic lesions and with more or feswer than or equal to three sites insvolsed. In patients
without apparent bone insvolvement. bone formation markers sere rarely elesvated. Consverselv. serum ICTP
was frequently found to be supranormal. showing it to be a non-specific marker for early detection of bone
metastases. As expected. values of bone formation markers progressisely increased in patients with ly-tic. mixed
and blastic lesions, but ICTP levels did not shosw any differences according to the types of bone appearances.
confirming previous reports of elesvated osteoclast activity also in patients with apparent blastic lesions. Serum
PTH increased significantly in patients with lytic compared w-ith patients with mixed and blastic appearances.
parallehing the bone formation markers. but CaCr showsed the opposite pattern. These data are compatible with
calcium entrapment in the bone in patients with increased osteoblast activity. This so called 'bone hunger
syndrome' is further confirmed by the finding that in the subgroup of blastic appearances CaCr diminished
whereas both ICTP and PTH increased according to the extent of tumour load in the bone.
Kevwords: bone metastases; bone turnosver: bone hunger s-ndrome
Metastatic tumours in the bone interfere with normal bone
remodelling by the local release of cytokines and growth
factors that increase osteoclast and or osteoblast activitv
(Mundy, 1991). This metabolic disruption results in increased
bone destruction (osteolysis). increased bone formation
(osteosclerosis) or both (Paterson. 1987: Carter. 1985).
Osteolytic metastases are the predominant type of bone
lesions in most cancers. whereas a sclerotic appearance is seen
in the majority of metastases from prostatic cancer (PC). in
about 10% of metastases from breast cancer (BC) and even
more rarely in those derived from other cancers (Stoll, 1983).
Assessment of metastatic disease in the skeleton has been
and remains a difficult issue. Metabolic interactions between
tumour and bone cells are relatively neglected. Information
from the imaging techniques (lytic, mixed or blastic
appearances at radiograph or computerised tomography.
hotspots at isotope scan) refers to focal lesions and relevant
morbiditv.
Efforts to achieve a biochemical assessment of tumour
activity are needed (Coleman. 1994). As the actual
production of paracrine agents involved in bone remodelling
cannot be directly estimated. a suitable approach is offered by
evaluating the consequent changes in rates of bone formation
and resorption by means of bone turnover markers (Coleman
et al.. 1988).
A number of indicators are of value when exploring
different aspects of bone cell function. Among those of bone
formation. bone-specific alkaline phosphatase (BALP) can
now be measured in blood more easily than in the past.
BALP is present on the surface of osteoblasts. but the
mechanism of its release in the circulation still remains
unclear (Azria. 1989). Osteocalcin (bone gla protein. BGP) is
a non-collagenous matrix protein of bone that is synthesised
by osteoblasts. A small fraction of the synthesised protein
does not accumulate in bone. but is secreted directlv into the
circulation. Serum levels of BGP can be viewed as a reliable
index of bone matrix svnthesis (Azria. 1989: Delmas. 1993).
A third indicator is the propeptide carboxy-terminal of type I
procollagen (PICP) (Meikko et al.. 1990). an extension
peptide cleaved off before the collagen molecules form
collagen fibrils. Type I collagen is the most abundant form
of collagen present in bone. but it is also widely distributed in
other tissues. Thus. PICP is a less specific marker for bone
formation than BALP or BGP.
Bone resorption is currentl1 esaluated bv collagen
degradation products. Urinar- hvdroxyproline has long
been employed in the past. Unfortunately. extraskeletal
sources. including dietarv constituents and serum proteins.
can also contribute to the excretion of this substance (Azria.
1989: Delmas. 1993). Recently, the urinary levels of
hydroxylysine glycosides (Moro et al.. 1993). pyridinoline
cross-linking amino acids (Uebelhart et al.. 1990). collagen
cross-linked N-telopeptide fragments (NTX) (Hanson et al..
1990) and the serum levels of carboxy-terminal telopeptides
of type I collagen (ICTP) (Risteli et al.. 1993) have been
reported to be more specific markers for bone resorption.
Additionally. the molar ratio of calcium to creatimnne (CaCr)
in an earlv-morning urine sample after an overnight fast may%
be viewed as a single and reproducible method of quantifying
calcium excretion (Peacock et al.. 1969: Campbell et al..
1983).
The aim of the present studys as to obtain information on
bone turnover by measuring serum and urinary parameters in
cancer patients with skeletal metastases stratified according to
radiological appearances and disease extension in bone.
Materials and methods
Patients
From January 1990 to December 1993 174 patients bearing
bone metastases from various primary tumours and 48
patients with advanced metastatic tumours without apparent
bone involvement (bone scan negative) were recruited into
the studv. Patient characteristics are shown in Tables I and
II
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Table I Characterstics of patients with bone metastases (n= 174) Tabke H Profile of patients without bone involvement (n=48)
Primary tumours
Breast
Lung
Prostate
Kidney
Urothelial
Colon
Gastric
Unknown
Thyroid
Head and neck
Ovary
Sarcoma
Uterus
Testicular
Myeloma
Sex
Male
Female
Age (years)
Median
Range
PS
0
1
2
3
4
Previous treatments
Chemotherapy
Endocrine therapy
Radiotherapy
Concomitant metastatic sites
Lung
Liver
Skin/lymph nodes
Bone appearances
Lytic
Mixed
Blastic
Number of sites involved
<3
>3
60
39
38
10
10
3
3
3
2
l
1
1
94
80
60
28-86
24
66
39
35
10
84
75
23
49
17
34
102
38
34
94
80
Breast, lung and prostate were the malignancies most
frequently represented. Most bone metastases were located in
the spine, ribs and pelvis. All patients had progressive disease
and had been off any systemic treatments for at least 1 month
and palliative radiotherapy on bone lesions for at least 3
months. A total of46patients wereevaluated at first recurrence
of disease before the start of any treatment, 84 patients were
previously submitted to chemotherapy, 23 to radiotherapy and
75 to endocrine therapy. Bisphosphonate treatment was
considered an exclusion criterion. None was suffering from
hepatic failure and none had less than 60 ml min-' creatinine
clearance. All patients gave their informed consent.
Diagnosis of bone metastases and assessment of the disease
extension
Diagnosis of bone involvement was performed with a bone
scan followed by radiological confirmation (radiograph) of
hotspots. Computerised tomography (CT) was performed to
discriminate lesions that appeared positive at scintigraphy
and negative at radiograph. We arbitrarily divided the whole
skeleton into the following areas: skull, cervical, dorsal,
lumbar spine, sacrum, right femur, left femur, right humerus,
left humerus, right ribs, left ribs, sternum, right pelvis, left
pelvis. According to radiological appearances on radiograph
and/or CT scan, patients were stratified as having more or
fewer than or equal to three sites involved.
Primary tumours
Breast
Lung
Urothelial
Oesophagus
Prostate
Kidney
Soft tissue sarcoma
Thyroid
Stomach
Thymus
Uterus
Colon
Ovary
Anus
Age (years)
Median
Range
Sex
Male
Female
PS
0
1
2
3
Sites of disease
Lung
Liver
Lymph nodes
Local
14
7
6
3
3
3
3
2
2
1
1
1
57
29-82
24
24
15
19
13
1
23
8
14
23
In all 102 patients were diagnosed as having lytic lesions,
38 mixed and 34 blastic. Overall 80 patients were found to
have more than three sites involved and 94 fewer than or
equal to three.
Marker assays
All samples were drawn or collected in the early morning after
an overnight fast and included spot urine specimens for
determination of calcium and creatinine and blood specimens
for assessment of calcium, creatinine, albumin, BALP, PICP,
BGP and ICTP. Urine collection was performed as follows:
the patients were maintained on an unrestricted diet; after a
10 h overnight fast, they emptied their bladders and the urine
was discarded. All subjects then drank 250-500 ml of
deionised water, after 1 h a second urine sample was collected
in a plastic container. Serum and urine samples were stored at
-70°C until analysis. Serum PICP, ICTP and BGP were
measured in duplicate using commercially available radio-
immunoassay (RIA) kits (Farmos Diagnostica, Ounsalo,
Finland and CIS Diagnostici, Santhia, Italy). The intra- and
inter-assay coefficients of variation were 4.2%, 4.5%, 4.3%
and 5.5%, 6.8%, 7.0%, respectively, between 20% and 80%
displacement values. Serum alkaline phosphatase (ALP) was
measured with a well-standardised kinetic colour test (Merck
Diagnostica, Darmstadt, Germany) using p-nitrophenylpho-
sphate as a substrate; the coefficients ofvariation were always
below 5% in a whole range of values. BALP was performed
using electrophoretic separation. Serum calcium (CaS) and
creatinine measurements were made with standard autoana-
lyser techniques. Calcium concentration was corrected to a
reference serum albumin of40 g L` using a correction factor
of0.02 mmol g-' albumin. Urinary excretion ofcalcium was
expressed as molar ratio of calcium to creatinine (CaCr,
mmol mmol-'). Serum PTH concentration (intact molecule)
(RIA kit, Nichols San Juan Capistrano; intra- and inter-assay
variations of 4.0 and 5.8) was also evaluated in the early
morning.To obtain the reference values of all biochemical markers
we recruited a healthy individual population of 128 males
and 115 females (mean age 51 + 15 years. range 28 -83 years).
Control subjects were first divided according to sex and
subsequently stratified according to age as follows: under 40s.
between 40 and 60, over 60s. The Kolomogroff-Smirnoff test
was used to assess the normal distribution of marker values
within each subgroup. The upper normal levels were defined
as the mean plus two standard deviations of the values in
each subgroup.
Statistical analysis
Differences between groups were tested using non-parametric
tests (Kruskall-Wallis one-way analysis of variance, Mann-
Whitney U-test). P<0.05 was regarded as significant. The
relationship between variables was assessed using the
Spearman correlation coefficient. SPSS package was used
for statistical computation (Norusis. 1990).
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Results
Changes in biochemical markers according to bone appearances
in patients with bone metastases
Figure 1 shows the scatterplots of serum concentrations of
serum indicators in bone metastatic patients. stratified into
three groups according to radiograph appearances. Supra-
normal levels of BALP (upper normal value between 68 and
75 U 1-1 with differences according to sex and age). PICP
(upper normal value between 190 and 210 pig I-1). BGP
(upper normal value 9.5-11.5 ng ml-1) were found more
frequently in patients with blastic and mixed lesions than in
those with lytic lesions. Conversely, supranormal rates of the
bone resorption marker. ICTP (upper normal value between
3.5 and 4.5 jpg 1-'). did not differ among the groups. A total
of 27 patients (15.5%) showed serum calcium levels above
2.65 mmol L-1 and eight patients had levels below
2.2 mmol L-l (4.6%). The percentages of hypercalcaemic
and hypocalcaemic patients were 19 102 (18.2%) and 3 102
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Figure 1 Scatterplot of serum levels of bone formation markers -carboxy-terminal propeptide of type I procollagen (PICP): bone
isoenzyme of alkaline phosphatase (BALP);
bone gla protein (BGP) -and bone collagen resorption -carboxy-terminal telopeptide of
type I collagen (ICTP)-in advanced cancer patients stratified as having no apparent bone involvement (NB). lytic bone metastases
(L). mnxed bone metastases (M) and blastic bone metastases (B). Values within or above the reference range are shown as full or
empty circles respectively. Lines represent the median value.
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(2.9%), 4/38 (10.5%) and 3/38 (7.9%) and 4/34 (11.7%) and
2/34 (5.9%) in the groups with lytic, mixed and blastic
appearances respectively. Serum PTH levels below the
detection threshold of the method were found in 25/102
(24.5%), 8/38 (21%) and 2/34 (5.8%) patients, respectively.
Conversely, the corresponding distributions of supranormal
levels (65 pg ml-') were 5/102 (4.9%), 5/38 (13%) and 10/34
(29.4%).
Medians and ranges are presented in Table HI. The bone
formation markers (BALP, BGP and PICP) were found to
increase progressively in patients with lytic, mixed and blastic
lesions. Patients with blastic appearances had lower urinary
CaCr than those with lytic and mixed lesions. Serum ICTP
values did not change according to the types of bone lesions.
Serum PTH behaved in a roughly similar way to the bone
formation markers, having a progressive increase in patients
with lytic to those with blastic appearances. Superimposable
patterns of all biochemical markers according to radiograph
appearances have been observed by analysing the patient
subset with disease apparently confined to the skeleton (data
not shown).
Table IV shows the correlation coefficients and the
relevant levels of significance obtained in our attempt to
quantify the strength of association between coupled
variables. Patients having mixed or blastic appearances were
considered as a single group. In the group of lytic lesions
significant correlations were found between ICTP and CaCr,
ICTP and BGP, and ICTP and PICP. A significant
correlation was found between serum calcium levels and
both ICTP and CaCr. The most evident relationship,
however, was that between PICP and BALP. In the group
of mixed and blastic lesions a strong correlation was found
between BGP and BALP. The correlation between ICTP and
BALP and between CaS and CaCr was also significant. PTH
levels did not correlate with any marker in the group of lytic
appearances but did significantly correlate with BALP and
ICTP in the group of mixed and blastic appearances. In the
latter group, PTH was inversely correlated with both serum
calcium and CaCr.
Markers ofbone turnover in patients without apparent bone
metastases
Medians and ranges ofexamined markers are shown in Table
Im. ICTP levels were lower than those of all subgroups of
bone metastatic patients (P<0.05). Urinary calcium excretion
was less than in patients with lytic and mixed lesions
(P<0.001), but not less than in patients bearing blastic
metastases. Serum levels of bone formation markers were
similar to those found in patients with lytic appearances.
BALP and PICP levels were lower than those ofpatients with
mixed and blastic lesions (P<0.001); BGP levels were lower
than those of patients with blastic appearances (P<0.001)
but were not lower than those of patients bearing mixed
lesions.
Serum PTH levels were higher than those of patients with
lytic appearances (P<0.001), superimposable to those of
patients with mixed metastases and lower (P<0.05) than
those of patients with blastic appearances. Supranormal PTH
levels were found in 4/48 (8.3%) patients and levels below the
threshold in 3/48 (6.2%). Values above the normal range of
BALP, BGP and PICP were found in a small number of
patients. Conversely, a relatively high number of patients
showed supranormal values of ICTP (Figure 1).
Markers ofbone turnover and extension ofdisease
Patients with lytic metastases and more than three bone sites
involved had medians of all markers higher than those with a
lower number. Only ICTP, BALP and PICP, however,
attained statistical significance (Table V). As far as patients
with mixed and blastic lesions were concerned (Table V), the
levels of either bone formation or collagen resorption
markers had an apparent tendency towards higher values in
the group with more extensive skeletal involvement but the
differences did not attain statistical significance except for
ICTP in patients with mixed lesions (P<0.01). CaCr and
PTH did not show appreciable changes as a function of the
extension of disease in patients with lytic and mixed lesions.
Table m Biochemical markers in bone metastatic patients stratified according to bone appearances
No bone metastases Lytic Mixed Blastic P*
PICP (UgV-')
Median 124 137 178 245 <0.001
Range 71 -364 40-512 77-600 10-1480
BGP (ug1-1)
Median 7.5 6.3 9.9 13.2 <0.001
Range 1.5-18.3 1.6-52 5-19 28-52
BALP (U-')
Median 26 29 123 310 <0.001
Range 5-227 5-295 15-1137 22-5400
CaS (mmoll')
Median 2.42 2.46 2.40 2.47 NS
Range 2.25-2.89 2.02-3.8 2.1 -2.9 2.01 -2.8
CaCr (mmolmmnol')
Median 0.12 0.33 0.40 0.14 <0.01
Range 0.02-0.6 0.04-6.4 0.01-3.45 0.01-2.4
ICTP (ug1-1)
Median 7.7 10.0 12.2 11.4 NS
Range 3.2-29.8 2.2-41.7 2.6-48.1 3.1-58.2
PITH (pgml-')
Median 37 25.5 35 48 <0.001
Range 15-89 15-91 15-120 15-190
*Kruskal-Wallis one-way analysis ofvariance.Bone tunove i cancer pawtin
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Table IV Correlations between vanrables
PICP BGP BALP ICTP CaS CaCr PTH
Patients with lltic appearances
PICP -
BGP 0.01 -
BALP 0.52** 0.13 -
ICTP 0.27* 0.32* 0.25 -
CaS 0.04 0.21 0.08 0.31*
CaCr -0.02 0.15 0.07 0.38* 0.31*
PTH 0.06 0.18 0.22 -0.11 -0.28* 0.14
Patients with blastic and mixed appearances
PICP -
BGP 0.24 -
BALP 0.27 0.64 -
ICTP 0.18 0.06 0.43* -
CaS 0.01 0.17 -0.11 -0.18 -
CaCr 0.33 0.09 0.27 0.31 0.32*
PTH 0.06 0.15 0.52** 0.46** -0.38** -0.31** -
Values are the coefficient ofcorrelation (Spearman r). *P<0.01. **P<0.001.
Table V Biochemical markers of bone turnover in bone metastatic patients according to the disease extent
Litic lesions Mixed lesions Blastic lesions
Markers (3 >3 p <3 >3 p <3 >3 p
PICP (ig11-) 120 170 <0.02 155 186 NS 243 286 NS
Range 40- 512 58 -355 93- 500 77-600 110-708 113-1480
BGP (ngml-') 6.6 5.9 NS 8.4 11.6 NS 12.6 14.4
Range 1.6-28.6 1.5- 52.0 1.5- 14.2 1.0- 19.0 6.0-20.7 2.8- 52.0
BALP (U 1 2') 7 43 0.05 83 123 NS 164 370 NS
Range 5 295 6 - 152 42 -681 22- 1137 46-629 22-5400
CaS (mmolF') 2.45 2.53 NS 2.33 2.39 NS 2.50 2.36 <0.02
Range 2.02-3.82 2.11-3.39 2.18-2.69 2.10-2.96 2.24-2.85 2.01 -2.69
Ca Cr 0.32 0.37 NS 0.21 0.42 NS 0.39 0.06 <0.01
(mmolmmot1) 0.01-6.4 0.02-5.25 0.01- 3.45 0.04-1.07 0.06-0.90 0.01 -2.42
Range
ICTP (jgg ) 8.9 12.9 <0.02 5.2 14.4 <0.01 9.1 12.1 NS
Range 2.2- 33.7 2.8-41.7 2.6- 18.2 2.8-58.2 4.4- 13.2 3.1 -58.2
PTH (pgml ) 26 23.5 NS 35 39 NS 39 64 <0.05
Range 15-90 15-90 15-98 9- 120 15-72 15-194
In those with blastic appearances, CaCr values were
significantly lower and serum PTH levels significantly higher
in patients with more than three bone sites in comparison
with those with a lower degree of bone involvement.
Discussion
Bone is a common site of metastatic cancer. There have been
significant advances in our knowledge of bone remodelling
and its disruption in malignancies (Mundy, 1991). Bone
turnover markers conceivably provide information on actual
osteoblastic and osteoclastic activities and hence may be of
clinical value in monitoring metastatic bone disease. In the
present study the marker of collagen breakdown (ICTP) was
found to be supranormal in about two out of three of
patients bearing advanced cancer irrespective of bone
appearances.
Serum ICTP is not as specific as some of the urine
collagen cross-link assays. nevertheless our data are
consistent with those of previous studies (Paterson et al..
1991; Pecherstrorfer et al., 1995) that reported higher levels
of urinary pyridinium cross-links in cancer patients without
bone metastases than in healthy subjects. Reduction of both
nutritional conditions and mobility may partially explain the
increased levels of collagen resorption in neoplastic patients.
The contribution to serum ICTP of extraskeletal sources
needs better definition. Notwithstanding limitations of this
indicator, one has to consider that generalised osteolysis may
also be caused by tumour secretion of PTHrP (Steward and
Broadus. 1990) and or tumour-derived cytokines or prosta-
glandins. independently of the presence of tumour cells in
bone (Paterson et al.. 1991). We believe, in any case. that
bone involvement should be taken into account as well as the
contribution to serum ICTP of non-skeletal involved tissues
(skin in particular) (Meikko et al.. 1990).
With regard to bone formation markers. they were above
the reference value in a small number of patients without
bone appearances and in about one out of three of those with
lytic appearances. As no patient in these groups was found to
have elevated bone formation markers without concomitantly
elevated bone resorption markers. it seems that raised
osteoblast function reflects the maintenance of the coupling
processes. although inadequate. to counteract effectively the
mechanisms responsible for bone loss.
Indices of bone synthesis increased significantly in patients
with lytic compared with those with mixed and blastic
appearances. but a somewhat unexpected finding was theBn arnovs in canew paMs
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absence of a consensual ICTP reduction. The discrepancies
between markers of osteoblast and osteoclast activities have
been confirmed analysing the patient subset with disease
apparently confined to the skeleton. Our data may be viewed
as consistent with previous reports of histomorphometric
evidence of bone resorption besides synthesis in apparently
pure blastic lesions (Clarke et al., 1991).
When considering albumin-corrected serum calcium
concentrations, subclinical hypercalcaemia in bone meta-
static patients is more frequent than previously thought,
but hypocalcaemia is also not so rare (Mundy, 1990; Riancho
et al., 1989). In the present series, 16% of patients had
calcium levels higher than normal (12% of them with clinical
signs of hypercalcaemia), whereas 4.6% had lower than
normal levels yet were asymptomatic. Hypercalcaemia was
more frequent in patients with lytic and mixed lesions. Serum
PTH showed an opposite pattern - values below the
detection limits were more frequently observed in patients
with lytic lesions and supranormal levels in those with blastic
appearances.
PTH stimulation of osteoclast activity could be a factor
accounting for the higher resorption rate observed in a
number ofthese latter patients. Correlations between markers
were sought in distinct populations of patients: those with
lytic lesions and those with mixed and blastic lesions.
Significant correlations were found between BALP and
PICP, but not BGP, in patients with lytic appearances, and
between BALP and BGP, but not PICP, in patients with
mixed/blastic ones. The reasons for these disrepancies are
unclear. The control of osteoblast activity is multifactorial
even in the absence of bone involvement from neoplastic
cells. Serum markers of bone synthesis may also display
divergent patterns in patients bearing non-malignant
disorders of bone turnover, such as acromegaly and Paget's
disease (Hosking, 1990; Terzolo et al., 1993).
In patients with mixed/blastic lesions the inverse relation-
ship between serum PTH and serum calcium values and the
parallelism between serum PTH and BALP suggest that a
secondary hyperparathyroidism may exist owing to calcium
entrapment in the bone. In these cases, the direct relationship
between PTH and ICTP could reflect the PTH effect on bone
collagen breakdown of tumour-free bone tissue (Rico et al.,
1990). Hyperparathyroidism (Rico et al., 1990) and hypopho-
sphataemia (Jacobs, 1983) have been described previously in
prostatic cancer patients with bone metastases. This
metabolic picture, called bone hunger syndrome (Rico et
al., 1990), may result in increased resorption and osteoma-
lacia in bone sites distant from tumour metastases (Urwin et
al., 1985) and could contribute to morbidity.
The procedure used by us to assess tumour extent refers
only to the number of sites involved and does not take into
account the percentage of bone involvement within each site.
Nevertheless, in all subgroups a more pronounced elevation
of marker levels was found in patients with more than three
metastatic sites when compared with those with less bone
involvement. Only one exception should be noted in the
general tendency of biochemical indices to parallel the
tumour extent. In patients with blastic lesions CaCr
diminished together with serum calcium, while increasing
both the tumour load and ICTP levels. This observation
seems to be in line with the postulated PTH increase and with
the concept that the pathogenesis of collagen loss in patients
with blastic lesions is different from that ofpatients with lytic
lesions.
In conclusion, the mismatch between bone formation and
resorption in cancer patients with skeletal involvement varies
consistently from patient to patient, according to radiograph
appearances, and recognises complex mechanisms. The
usefulness of a biochemical assessment of bone metabolism
in metastatic patients eligible for antineoplastic treatments
remains to be established. The relationship with the
appearance extension at radiology augurs well for their
employment in follow-up studies.
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